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(2S,3S)-3-[N-Cbz-L-Leucinyl]amino-2-hydroxy-4-phenylbutanoic acid 5 dimerised on treatment 
with EDCI and HOBT to give the symmetrical [1,4]dioxane-2,5-dione-based peptidomimetic 6. 
 






An endless array of organic compounds exist that exhibit an equally endless array of 
biological activities. These compounds function by simply presenting a well-defined topology to 
a complementary receptor or enzyme in spite of a diversity of molecular structure and biological 
mechanism of action. It therefore follows that new classes of bioactives would result from 
simply generating new molecular topologies. One way to achieve this objective is to tether 
known bioactive molecules onto an appropriate molecular scaffold to generate a new, overall 
molecular topology. The choice of scaffold needs to allow the ready chemical attachment of a 
range of simple molecules that possess a diversity of structure and function, perhaps in a 
combinatorial fashion. The result of such a union is a compound whose overall topology is 
controlled by the nature and combination of its constituents. 
This idea has been used to generate important bioactives that contain a core scaffold and a 
range of attached ligands that can number anywhere from a few (e.g. protease inhibitors that 
possess a core isosteric unit to which are attached enzyme binding domains)1 to many (e.g. a 
dendrimer).2 Such hybrid compounds provide leads for important biological probes and potential 
therapeutics with improved potency, stability and in many cases, vastly different biological 
properties and mechanisms of action relative to their separate components. There is, therefore, a 
clear need for new and general molecular scaffolds. In this paper we present a simple example of 
this idea that allows a peptide, or conceivably another suitable functionalized molecule, to be 
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attached at two sites on a heterocyclic scaffold (see compound 6). The compound presented here 
is simple to prepare as a crystalline solid, and demonstrates this principle. Closely related 
compounds have been reported as inhibitors of Calpains,3 an over activity of which is associated 
with a number of important human diseases.4 
 
 
Results and Discussion 
 
The optically active peptidomimetic scaffold 6 was prepared as detailed in the Scheme below. In 
the key step, a solution of (2S,3S)-3-[N-Cbz-L-leucinyl]amino-2-hydroxy-4-phenylbutanoic acid 
5 in DMF was reacted with a solution of 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide 
hydrochloride (EDCI) and hydroxybenztriazole (HOBT) in dichloromethane containing 
diisopropylethylamine (DIEA) to give 6 as a stable colorless solid in 74% yield. The starting 
material 5 was prepared in three steps as shown in the Scheme.  The known5 α-hydroxy β-amino 
acid 2 was N-deprotected with HBr in acetic acid to give a mixture of 3a and 3b (9:1), which was 
subsequently coupled with N-Cbz-L-leucine under standard EDCI conditions to give 4a and 4b 
(9:1). This mixture was finally hydrolysed to give the desired derivative 5 (see step iii) in 69% 
over two steps. It is interesting to note that the ratio of 3a to 3b obtained in step i was dependent 
upon the concentration of 2 used in the reaction. Product ratios of 4:1, 9:1, 12:1 and 19:1 were 
obtained for concentrations of 0.26, 0.97, 1.47 and 2.00 M, respectively. 
The dimeric nature of 6 was confirmed by a combination of 1H NMR, 13C NMR and mass 
spectrometry. The two-fold axis of symmetry in the dimer 6 was confirmed by the presence of 
only twenty peaks in the 13C NMR spectrum while high resolution mass spectral data was 
consistent with the dimeric structural formula [C48H57O10N4 (M+1)+].  In addition, the 1H NMR 
of 6 revealed a resonance at 5.49 ppm that was shown to correspond with H2 by a 2D NMR 
COSY experiment - a key correlation was observed in the COSY experiment between H3 (4.66 
ppm) and H2 (5.49 ppm). Importantly, the chemical shift of H2 is consistent with O-acylation6 
where a similar chemical shift was observed for H2 in 4b (5.53 ppm), whereas H2 in the 
corresponding alcohol 4a resonated further upfield at 4.29 ppm. 
In this paper we have presented the synthesis of an interesting and new class of 
peptidomimetic molecular scaffold whose architecture should be amenable to attaching a wide 
range of amino acid R groups and thus the presentation of a diverse range of topologies. 
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2 3a R = H3b R = Ac
4a R = H








Sheme 1. Reagents and conditions: (i) 33% HBr in AcOH, 20 min, 9 (3a):1 (3b); (ii) N-Cbz-L-
Leu, EDCI, HOBT, DIEA, DMF, DCM, 16 h, 9 (4a): 1 (4b); (iii) LiOH, MeOH, H2O, 4h; (iv) 





General Procedures. 1H NMR spectra were obtained on a Varian Inova spectrometer, operating 
at 500 MHz. Coupling constants (J) are quoted in Hz. 13C NMR spectra were obtained on a 
Varian Unity 300 spectrometer, operating at 75 MHz, with a delay (D1) of 1 s. Electron impact 
(EI) mass spectra were detected on a Kratos MS80 RFA mass spectrometer operating at 4000 V 
(accelerating potential) and 70 eV (ionisation energy) using a source temperature of 200-250°C. 
 
(2S,3S)-3-[N-Cbz-L-Leucinyl]amino-2-hydroxybenzenebutanoic acid (5). Compound 25 (500 
mg, 1.47 mmol) was dissolved in a solution of HBr in acetic acid (33%, 1.0 ml) and the resulting 
mixture was stirred at rt for 20 min. The addition of ether (2 mL) caused the amine salt to 
precipitate. The solvent was drawn off and the resulting residue retained. To the etheral solution 
was added petroleum ether (4 mL) to give a further precipitate. The solvent was drawn off and 
the two batches of solid were combined and dried to give a mixture (397 mg, 12:1 by 1H NMR) 
of the amine salts 3a (86%) and 3b(6%) as a brown tar. Selected data from the mixture: 1H NMR 
3a (D2O) δ 7.19-7.31 (5H, m, ArH), 4.51 (1H, d, J = 2.5 Hz, CHCHOH), 4.03 (1H, m, 
CHCHOH), 3.38 (3H, s, CH3), 2.89 (2H, m, CH2Ph). 1H NMR 3b (D2O) δ 7.19-7.31 (5H, m, 
ArH), 5.41 (1H, d, J = 1.7 Hz, CHCHOAc), 4.25 (1H, m, CHCHOAc), 3.41 (3H, s, COOCH3), 
3.00 (2H, m, CH2Ph), 2.18 (3H, s, OCOCH3). 
To a mixture of 3a and 3b (64 mg, 9:1 by 1H NMR, 0.22 mmol) were added EDCI (47 mg, 
0.25 mmol) and HOBT (32 mg, 0.24 mmol). A solution (1.0 M) of N-Cbz-L-leucine in N-
methylpyrrolidinone (240 µL, 0.24 mmol), DMF (250 µL) and DIEA (43 µL, 0.25 mmol) were 
then added and the reaction mixture was stirred overnight at rt under nitrogen. The reaction 
ISSN 1424-6376 Page 74 ©ARKAT 
Issue in Honor of Prof. Jim Coxon ARKIVOC 2006 (iii) 72-76 
mixture was diluted with ethyl acetate (4 mL) and washed with 10% aqueous HCl (3 x 2 mL), 
saturated NaHCO3 (3 x 2 mL), brine (2 mL), dried over MgSO4 and concentrated in vacuo to 
give a mixture (9:1 by 1H NMR) of 4a and 4b (69 mg, 69%) as a white solid. Data from the 
mixture: [MS (FAB): 499 [(M+1)+ 4b], 457 [(M+1)+ 4a], 414, 307, 210, 154, 136]; mp 138-144 
°C; IR (CHCl3) 3688, 3416, 2961, 1734, 1676, 1601, 1500, 1440 cm-1. 1H NMR 4a (CDCl3) δ 
7.14-7.35 (10H, m, ArH), 6.51 (1H, d, J = 8.8 Hz, PheNH), 5.09 (3H, m, CbzCH2 & CbzNH), 
4.51 (1H, ddd, J = 2.9, 7.3, 16.1 Hz, CHCHOH), 4.29 (1H, br s, CHCHOH), 4.11 (1H, m, 
NHCHCO), 3.59 (3H, s, OCH3), 2.79 (2H, m, PheCH2), 1.61 (3H, m, LeuCH & LeuCHA), 1.39 
(1H, m, LeuCHB), 0.89 (6H, m, 2 x LeuCH3); 13C NMR 4a (CDCl3) δ 172.8 (COOMe), 172.0 
(NHCHCO), 156.2 (CbzCO), 136.7 (PheArC), 136.0 (CbzArC), 129.3, 128.5, 128.3, 128.3, 
128.1, 126.7 (ArCH), 72.0 (CHOH), 67.2 (CbzCH2), 53.7 (NHCHCO), 53.0 (CHCHOH), 52.5 
(COOCH3), 41.0 (LeuCH2), 35.4 (PheCH2), 24.6 (LeuCH), 22.8 (Leu(CH3)A), 21.9 (Leu(CH3)B). 
1H NMR 4b (CDCl3) δ 6.42 (1H, m, PheNH), 5.53 (1H, s, CHOAc), 3.63 (3H, s, COOCH3), 2.16 
(3H, s, OCOCH3). 
To the mixture of 4a and 4b (60 mg, 0.13 mmol, 9:1 by 1H NMR) at 0 °C was added a 
solution of 0.25 M lithium hydroxide (1.5 parts) in 2:1 methanol/water. After the reaction 
mixture was stirred for 0.5-4 h, sufficient 1N aqueous HCl was added to acidify the solution (pH 
5 by Universal Indicator) and the methanol was evaporated in vacuo. Water was added to the 
residue and the organics were extracted with ethyl acetate. The combined organic extracts were 
washed with water, brine, dried over MgSO4 and concentrated in vacuo to the acid 5 (58 mg, qu) 
as a white solid. 1H NMR (CD3OD) δ 7.82 (1H, d, J = 9.3 Hz, CbzNH), 7.33 (5H, m, ArH), 7.10-
7.19 (5H, m, ArH), 5.07 (2H, m, CbzCH2), 4.49 (1H, m, CHCHOH), 4.17 (1H, d, J = 4.4 Hz, 
CHCHOH), 4.07 (1H, m, NHCHCO), 2.80 (2H, m, PheCH2), 1.58 (1H, m, LeuCH), 1.33 (2H, 
m, LeuCH2), 0.88 (6H, m, 2 x LeuCH3); 13C NMR (CD3OD) δ 175.8 & 175.2 (CHCONH & 
COOH), 158.6 (CbzCO), 139.6 (PheArC), 138.4 (CbzArC), 130.7, 129.8, 129.6, 129.3, 129.2, 
127.6 (ArCH), 73.9 (CHOH), 68.0 (CbzCH2), 55.4 (NHCHCO), 54.8 (CHCHOH), 42.5 
(LeuCH2), 36.4 (PheCH2), 26.1 (LeuCH), 23.6 (Leu(CH3)A), 22.2 (Leu(CH3)B); [MS (FAB): 465 
(M+Na)+, 443, 399, 286, 176, 153, 136; HRMS (FAB) calcd for C24H30O6N2Na (M+Na)+ 
465.2002, found 465.1996]; mp 131-134 °C; IR (CHCl3) 3433, 2963, 1720, 1660, 1510, 1456, 
1340, 1217 cm-1. 
Dimer 6. To a solution of 5 (14 mg, 32 µmol) in DMF (1 mL) was added EDCI (8 mg, 41 µmol), 
HOBT (7 mg, 47 µmol), dichloromethane (1 mL) and DIEA (6 µL, 35 µmol). The reaction 
mixture was stirred overnight at rt before being diluted with dichloromethane (10 mL), washed 
with 10% aqueous HCl (10 mL), brine (10 mL), dried over MgSO4, and concentrated in vacuo to 
afford 6 (10 mg, 74%) as a white solid. 1H NMR (300Mz, DMSO) δ 8.28 (2H, d, J = 8.2 Hz, 
PheNH), 7.16-7.35 (22H, m, arom & CbzNH), 5.49 (2H, brs, H2), 5.01 (4H, s, CbzCH2), 4.66 
(2H, m, H3), 4.05 (2H, m, Leu-αH), 2.81 (4H, m, PheCH2), 1.49 (2H, m, LeuCH), 1.36 - 1.27 
(4H, m, LeuCH2), 0.81 (12H, m, LeuCH3); 13C NMR (DMSO) δ 172.1 (ring CO), 165.7 
(LeuCO), 155.4 (CbzCO), 137.6, 136.7, 128.7, 128.1, 128.0, 127.6, 127.5, 126.1, 77.6 (C2), 65.2 
(CbzCH2), 52.8 (Leu-αC), 49.9 (C3), 40.7 (LeuCH2), 33.8 (PheCH2), 23.9 (LeuCH), 22.6 
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(LeuCH3), 21.3 (LeuCH3); [MS (ES): 871 (M+Na)+, 849 (M+1)+, 647, 556, 537, 464, 316, 289, 
275, 249; HRMS (ES) calcd for C48H57O10N4 (M+1)+ 849.408, found 849.405]; RF 0.19 (1:4 
ethyl acetate-dichloromethane); IR (CHCl3) 3628, 3354, 1767, 1722, 1683, 1228 cm-1; [α]D - 78 ° 
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